Product Pipeline

Beyond Symptom Management to True Joint Regeneration

For decades, osteoarthritis (OA) treatments have been trapped in a cycle of standalone pain modulation. At PawThNeo, we believe true innovation must do more than mask symptoms; it must target underlying structural degradation to actively promote joint repair.

Multiple 2025–2026 veterinary papers, including reports in the Journal of the American Veterinary Medical Association document alarming musculoskeletal adverse events linked to leading anti-NGF treatments. These include rapidly progressive osteoarthritis (RPOA), tendon injuries, and catastrophic joint fractures. Furthermore, the FDA has highlighted severe neurological adverse events associated with these treatments, ranging from ataxia and paresis to seizures.

Our Approach: Engineered for Regeneration

Our R&D pipeline is dedicated entirely to precision protein therapeutics combination that will target disease modification and tissue regeneration in OA.

At PawThNeo, we recognize that true biopharmaceutical innovation must be paired with rigorous capital discipline. To maximize ROI and rapidly de-risk our core pipeline, we employ a Vet-First, Human-Second translational strategy.